Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study to Evaluate Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

Next Previous
Search
Trial Profile

A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study to Evaluate Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CD 388 (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NAVIGATE
  • Sponsors Cidara Therapeutics

Most Recent Events

  • 01 May 2025 According to Cidara Therapeutics media release, Nicole Davarpanah, M.D., J.D. recently promoted to chief medical officer (CMO), and Corrina Pavetto- recently promoted to senior vice president, clinical development- have played a significant leadership role in the execution of the NAVIGATE Study and the revision of its statistical analysis plan.
  • 18 Mar 2025 According to a Cidara Therapeutics media release, company announced upcoming presentation of Phase 2b NAVIGATE trial at the 38th International Conference on Antiviral Research (ICAR) taking place from March 17-21, 2025 in Las Vegas, Nevada.
  • 06 Mar 2025 According to a Cidara Therapeutics media release,a potential early analysis of efficacy data from the ongoing CD388 Phase 2b NAVIGATE study is expected in the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top